FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

64 letters match. Newest first.

  1. Central Admixture Pharmacy Services, Inc.

    FDA warned sterile drug compounder Central Admixture Pharmacy Services (Phoenix) that dirty areas and weak sterility testing made its drugs adulterated.

    High risk
  2. US Specialty Formulations, LLC

    US Specialty Formulations, a drug compounder registered as an outsourcing facility, made sterile compounded drugs under insanitary conditions.

    High risk
  3. New England Life Care, Inc. dba Advanced Compounding Solutions

    FDA cites Advanced Compounding Solutions for insanitary sterile-drug production and CGMP failures after a 2022 inspection.

    High risk
  4. Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC

    FDA warned Nephron Sterile Compounding Center about insanitary sterile drug production and sterility assurance failures found in a 2022 inspection.

    High risk
  5. Nephron SC Inc.

    Nephron SC's sterile drug manufacturing had unresolved cross-contamination and microbial contamination, making its drugs adulterated.

    High risk
  6. Hybrid Pharma, LLC

    FDA warned outsourcing facility Hybrid Pharma of Deerfield Beach, Florida, that sterile compounding violations made its drugs adulterated and unapproved.

    High risk
  7. Apothecary Health Solutions/Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop

    FDA cited Carie Boyd's Prescription Shop for compounded drugs that failed outsourcing-facility labeling and reporting rules.

    Medium
  8. Infusion Options, Inc.

    FDA found Infusion Options produced sterile compounded drugs under insanitary conditions and failed 503B labeling and reporting rules.

    High risk
  9. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warns Empower Pharmacy its compounded drugs missed outsourcing-facility conditions, including labeling and adverse-event reporting.

    Medium
  10. AnazaoHealth Corporation

    AnazaoHealth Corporation compounded drugs without meeting 503B conditions, including inadequate adverse event reporting.

    Medium
  11. Maitland Labs of Central Florida

    FDA warns Maitland Labs of Central Florida over sterile compounded drugs with manufacturing quality failures, mislabeling, and unapproved new drug violations.

    High risk
  12. Farmakeio Outsourcing LLC

    FDA warns Farmakeio Outsourcing over inadequate adverse event reporting and unapproved, misbranded compounded testosterone pellets.

    Medium
  13. Exela Pharma Sciences LLC

    FDA warns Exela Pharma Sciences that poor adverse event reporting left compounded drugs unapproved and with labeling violations.

    Medium
  14. American Specialty Pharmacy, Inc. dba ASP Cares

    FDA warned outsourcing facility ASP Cares about sterile compounded drugs made under insanitary conditions and with CGMP violations.

    High risk